Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

Biotronik, DREAMS, BIOSOLVE-II trial, bioresorbable stent, magnesium

Image courtesy of Biotronik Inc.

News | February 19, 2015
February 19, 2015 — Biotronik announced the completion of enrollment in the BIOSOLVE-II trial — a clinical study...
MiStent SES, Micell Technologies, Europe, bioresorbable stents
News | February 17, 2015
February 17, 2015 — Micell Technologies, Inc. announced the commercial availability of the MiStent sirolimus-eluting...
Fantom, Reva Medical, Rutgers, bioresorbable stents

Image courtesy of Reva Medical Inc.

News | February 12, 2015
February 12, 2015 — A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers,...
bioresorbable stents

Abbott's Absorb bioresorbable stent

Feature | December 31, 2014 | Dave Fornell
Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely...
stents, bioresorbable, clinical trial, clinical study

Image courtesy of Reva

News | December 31, 2014
December 31, 2014 — Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. The...
Boston Scientific, EVOLVE II, Synergy, bioresorbable stent
News | December 10, 2014
December 10, 2014 — In the first successful United States trial of a bioabsorbable polymer stent, the Boston Scientific...
Stentys, coronary stent, MiStent SES, Micell Technologies Inc.
News | November 14, 2014
Nov. 14, 2014 — Micell Technologies Inc. announced commercialization plans for its MiStent Sirolimus Eluting Absorbable...
DAIC Editor Dave Fornell

DAIC Editor Dave Fornell

News | November 03, 2014
By Dave Fornell, editor of DAIC Magazine The key take away messages from the 26th annual Transcatheter Cardiovascular...
Feature | October 08, 2014
October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb...
News | October 07, 2014
October 7,2014 — Amaranth Medical announced patient enrollment in multiple centers in Colombia, South America in MEND-...
Blog | September 26, 2014
By Dave Fornell, editor of DAIC Magazine The key take away messages from the 26th annual Transcatheter Cardiovascular...
News | September 26, 2014
September 26, 2014 — A first-of-its kind study comparing the safety and efficacy of biodegradable polymer sirolimus-...
News | September 24, 2014
September 24, 2014 — A new study that compares the use of an everolimus-eluting bioresorbable vascular scaffold (BVS)...
ABSORB II Study DES Xience Abbot Vascular
Feature | September 24, 2014
September 24, 2014 — Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective...
Videos | Stents Bioresorbable | September 24, 2014
DAIC Editor, Dave Fornell, interviews  Jim Hermiller, M.D., FACC, director of interventional cardiology, St. Vincent...